Knockout of A3 adenosine receptors reduces mouse intraocular pressure.

PURPOSE To test the putative role of A(3) adenosine receptors (ARs) in modulating intraocular pressure (IOP). METHODS IOP was monitored for up to 32 minutes in A3-knockout (A3AR-/-) and A3AR+/+ control mice by the servo-null approach. The IOP responses to adenosine, A3AR agonists and A3AR antagonists were studied singly or in combination in both strains. RESULTS IOP was significantly lower in A3AR-/- mice (12.9 +/- 0.7 mm Hg) than in A3AR+/+ control animals (17.4 +/- 0.6 mm Hg). The nonselective AR agonist adenosine produced a much smaller increase in IOP (2.2 +/- 0.8 mm Hg) in the knockout than in A3AR+/+ control mice (14.9 +/- 2.4 mm Hg). The A3-selective agonist IB-MECA did not affect IOP in A3-knockout mice, but raised it in A3AR+/+ mice. The highly selective A3AR antagonist MRS 1191 did not affect IOP in A3AR-/- mice, but lowered it in A3AR+/+ control mice. Preadministering MRS 1191 did not affect the small adenosine-triggered increase in IOP in A3AR-/- mice, but markedly attenuated adenosine's effects on IOP in A3AR+/+ control mice. MRS 1523, an A3AR antagonist less selective than MRS 1191 in rats, decreased IOP in both A3AR-/- and A3AR+/+ animals. As in black Swiss outbred mice and other mammalian species, reducing aqueous humor inflow with acetazolamide lowered IOP and administering water intraperitoneally increased IOP in both A3AR-/- and A3AR+/+ mice. CONCLUSIONS The reduced IOP and altered purinergic responses of IOP in A3AR knockout mice support the conclusion that A3ARs contribute to the regulation of IOP.

[1]  W. Bao,et al.  Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. , 2001, Journal of molecular and cellular cardiology.

[2]  P. Russell,et al.  Development and Characterization of an Immortal and Differentiated Murine Trabecular Meshwork Cell Line , 2005 .

[3]  S. Moro,et al.  Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. , 1999, Journal of medicinal chemistry.

[4]  M. Jacobson,et al.  Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. , 2000, The Journal of clinical investigation.

[5]  H. Gavras,et al.  A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. , 2000, Biochimica et biophysica acta.

[6]  Douglas R. Anderson,et al.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[7]  Gauderman Wj,et al.  Sample size calculations for ophthalmologic studies. , 1992 .

[8]  Kyong-Tai Kim,et al.  Pharmacological characterization of adenosine receptors in PGT‐β mouse pineal gland tumour cells , 2001, British journal of pharmacology.

[9]  M. Civan,et al.  Similarity of A(3)-adenosine and swelling-activated Cl(-) channels in nonpigmented ciliary epithelial cells. , 2000, American journal of physiology. Cell physiology.

[10]  Beverly H. Koller,et al.  Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.

[11]  C. Crosson Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. , 2001, Investigative ophthalmology & visual science.

[12]  Z. Yang,et al.  Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. , 2001, American journal of physiology. Heart and circulatory physiology.

[13]  K. Jacobson,et al.  Pharmacological characterization of novel A3 adenosine receptor-selective antagonists , 1997, Neuropharmacology.

[14]  Michael G. Anderson,et al.  Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice , 1999, Nature Genetics.

[15]  D. Snydacker,et al.  Adler's Physiology of the Eye. Clinical Application , 1981 .

[16]  W. Barlow,et al.  Sample size calculations for ophthalmologic studies. , 1992, Archives of ophthalmology.

[17]  Douglas R. Anderson,et al.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[18]  P. Kaufman,et al.  Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. , 1997, Experimental eye research.

[19]  C. Crosson Adenosine receptor activation modulates intraocular pressure in rabbits. , 1995, The Journal of pharmacology and experimental therapeutics.

[20]  J. Linden Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. , 2001, Annual review of pharmacology and toxicology.

[21]  M. Civan,et al.  Reliable measurement of mouse intraocular pressure by a servo-null micropipette system. , 2001, Investigative ophthalmology & visual science.

[22]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[23]  K. Jacobson,et al.  Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells. , 2000, The Journal of membrane biology.

[24]  M. Civan,et al.  Similarity of A3-adenosine and swelling-activated Cl− channels in nonpigmented ciliary epithelial cells , 2000 .

[25]  R. Stone,et al.  A1‐, A2A‐ and A3‐subtype adenosine receptors modulate intraocular pressure in the mouse , 2001, British journal of pharmacology.

[26]  R. Stone,et al.  A3 adenosine receptors regulate Cl-channels of nonpigmented ciliary epithelial cells. , 1999, American journal of physiology. Cell physiology.

[27]  S. Moro,et al.  Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. , 1998, Journal of medicinal chemistry.

[28]  C. Crosson,et al.  Characterization of ocular hypertension induced by adenosine agonists. , 1996, Investigative ophthalmology & visual science.

[29]  R. Stone,et al.  Inhibitors of NHE-1 Na+/H+ exchange reduce mouse intraocular pressure. , 2002, Investigative ophthalmology & visual science.